JP2015520221A - カンシル酸塩 - Google Patents

カンシル酸塩 Download PDF

Info

Publication number
JP2015520221A
JP2015520221A JP2015517850A JP2015517850A JP2015520221A JP 2015520221 A JP2015520221 A JP 2015520221A JP 2015517850 A JP2015517850 A JP 2015517850A JP 2015517850 A JP2015517850 A JP 2015517850A JP 2015520221 A JP2015520221 A JP 2015520221A
Authority
JP
Japan
Prior art keywords
dementia
disease
alzheimer
indene
cyclohexane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015517850A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015520221A5 (enrdf_load_stackoverflow
Inventor
マーティン・ハンス・ボーリン
クレイグ・ロバート・スチュアート
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2015520221A publication Critical patent/JP2015520221A/ja
Publication of JP2015520221A5 publication Critical patent/JP2015520221A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2015517850A 2012-06-21 2013-06-20 カンシル酸塩 Pending JP2015520221A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261662592P 2012-06-21 2012-06-21
US61/662,592 2012-06-21
PCT/GB2013/051606 WO2013190302A1 (en) 2012-06-21 2013-06-20 Camsylate salt

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018021595A Division JP6509393B2 (ja) 2012-06-21 2018-02-09 カンシル酸塩

Publications (2)

Publication Number Publication Date
JP2015520221A true JP2015520221A (ja) 2015-07-16
JP2015520221A5 JP2015520221A5 (enrdf_load_stackoverflow) 2016-08-12

Family

ID=48746084

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015517850A Pending JP2015520221A (ja) 2012-06-21 2013-06-20 カンシル酸塩
JP2018021595A Active JP6509393B2 (ja) 2012-06-21 2018-02-09 カンシル酸塩

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018021595A Active JP6509393B2 (ja) 2012-06-21 2018-02-09 カンシル酸塩

Country Status (42)

Country Link
US (1) US10548882B2 (enrdf_load_stackoverflow)
EP (2) EP2864316B1 (enrdf_load_stackoverflow)
JP (2) JP2015520221A (enrdf_load_stackoverflow)
KR (1) KR102123708B1 (enrdf_load_stackoverflow)
CN (2) CN104411697B (enrdf_load_stackoverflow)
AP (2) AP2014008137A0 (enrdf_load_stackoverflow)
AR (2) AR091495A1 (enrdf_load_stackoverflow)
AU (2) AU2013279109B2 (enrdf_load_stackoverflow)
BR (2) BR122016014302B1 (enrdf_load_stackoverflow)
CA (1) CA2875589C (enrdf_load_stackoverflow)
CL (1) CL2014003374A1 (enrdf_load_stackoverflow)
CO (1) CO7151486A2 (enrdf_load_stackoverflow)
CR (2) CR20140571A (enrdf_load_stackoverflow)
CY (1) CY1119505T1 (enrdf_load_stackoverflow)
DK (1) DK2864316T3 (enrdf_load_stackoverflow)
DO (1) DOP2014000268A (enrdf_load_stackoverflow)
EC (1) ECSP14032215A (enrdf_load_stackoverflow)
ES (1) ES2618939T3 (enrdf_load_stackoverflow)
HR (1) HRP20170359T1 (enrdf_load_stackoverflow)
HU (1) HUE033376T2 (enrdf_load_stackoverflow)
IL (1) IL236131A0 (enrdf_load_stackoverflow)
IN (1) IN2014DN10088A (enrdf_load_stackoverflow)
LT (1) LT2864316T (enrdf_load_stackoverflow)
MA (2) MA39259B1 (enrdf_load_stackoverflow)
ME (1) ME02633B (enrdf_load_stackoverflow)
MX (1) MX354214B (enrdf_load_stackoverflow)
NI (1) NI201400146A (enrdf_load_stackoverflow)
NZ (2) NZ702742A (enrdf_load_stackoverflow)
PE (1) PE20150670A1 (enrdf_load_stackoverflow)
PH (2) PH12014502803A1 (enrdf_load_stackoverflow)
PL (1) PL2864316T3 (enrdf_load_stackoverflow)
PT (1) PT2864316T (enrdf_load_stackoverflow)
RS (1) RS55815B1 (enrdf_load_stackoverflow)
RU (1) RU2638175C2 (enrdf_load_stackoverflow)
SG (1) SG11201407934UA (enrdf_load_stackoverflow)
SI (1) SI2864316T1 (enrdf_load_stackoverflow)
SM (1) SMT201700142T1 (enrdf_load_stackoverflow)
TN (1) TN2014000491A1 (enrdf_load_stackoverflow)
TW (2) TWI639591B (enrdf_load_stackoverflow)
UA (1) UA114196C2 (enrdf_load_stackoverflow)
WO (1) WO2013190302A1 (enrdf_load_stackoverflow)
ZA (1) ZA201500408B (enrdf_load_stackoverflow)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8415483B2 (en) 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
ES2566373T3 (es) 2011-10-10 2016-04-12 Astrazeneca Ab Inhibidores monofluoro beta-secretasa
US9000184B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000183B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000182B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab 2H-imidazol-4-amine compounds and their use as BACE inhibitors
US9000185B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cycloalkyl ether compounds and their use as BACE inhibitors
US10053453B2 (en) 2014-10-07 2018-08-21 Astrazeneca Ab Compounds and their use as BACE inhibitors
JP6546410B2 (ja) * 2015-02-23 2019-07-17 ローム株式会社 電力供給装置、acアダプタ、acチャージャ、電子機器および電力供給システム
AR107783A1 (es) * 2016-03-15 2018-06-06 Lilly Co Eli Terapia de combinación
CN109195630A (zh) * 2016-03-15 2019-01-11 阿斯利康(瑞典)有限公司 用于治疗与淀粉样蛋白β累积相关的病症的BACE抑制剂和抗体或抗原结合片段的组合
EP3937935A1 (en) * 2019-03-14 2022-01-19 Astrazeneca AB Lanabecestat for weight loss

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009539983A (ja) * 2006-06-12 2009-11-19 シェーリング コーポレイション 複素環式アスパルチルプロテアーゼ阻害薬
WO2010105179A2 (en) * 2009-03-13 2010-09-16 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
WO2011002408A1 (en) * 2009-07-02 2011-01-06 Astrazeneca Ab Novel compounds for treatment of neurodegeneration associated with diseases, such as alzheimer's disease or dementia
JP2014504300A (ja) * 2010-12-22 2014-02-20 アストラゼネカ・アクチエボラーグ 化合物及びbace阻害剤としてのその使用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100452491B1 (ko) * 2001-03-29 2004-10-12 한미약품 주식회사 신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법
JP4273406B2 (ja) 2001-06-01 2009-06-03 小野薬品工業株式会社 アルドース還元酵素阻害剤を有効成分とする脱髄性疾患または脱髄を伴う疾患治療剤
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
ATE445399T1 (de) 2004-03-22 2009-10-15 Lilly Co Eli Pyridyl-derivate und ihre verwendung als mglu5- rezeptorantagonisten
KR20080029965A (ko) 2005-06-14 2008-04-03 쉐링 코포레이션 아스파르틸 프로테아제 억제제
TW200734311A (en) 2005-11-21 2007-09-16 Astrazeneca Ab New compounds
EP1954682A4 (en) 2005-11-21 2011-11-09 Astrazeneca Ab NOVEL 2-AMINO-IMIDAZOLE-4-ONE COMPOUNDS AND THEIR USE IN THE MANUFACTURE OF A MEDICAMENT FOR USE IN THE TREATMENT OF COGNITIVE DEFICIENCY, ALZHEIMER'S DISEASE, NEURODEGENERATION AND DEMENTIA
CA2633992A1 (en) 2005-12-21 2007-07-05 Boehringer Ingelheim International Gmbh Pyrimidine derivatives useful as inhibitors of pkc-theta
WO2007100536A1 (en) 2006-02-24 2007-09-07 Wyeth DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE
WO2008076044A1 (en) 2006-12-20 2008-06-26 Astrazeneca Ab Novel 2-amino-5, 5-diaryl-imidazol-4-ones
JP2010517963A (ja) 2007-02-01 2010-05-27 グラクソ グループ リミテッド 神経学的および神経精神病学的障害の治療におけるGlyT1トランスポーター阻害薬としての8−オキサ−1,4−ジアザスピロ[4,5]デク−3−エン−1−イルおよび1,4,8−トリアザスピロ[4,5]デク−3−エン−1−イルアセトアミド誘導体
CA2686589A1 (en) 2007-05-07 2008-11-13 Schering Corporation Gamma secretase modulators
WO2009100169A1 (en) 2008-02-06 2009-08-13 Glaxo Group Limited Dual pharmacophores - pde4-muscarinic antagonistics
FR2929943B1 (fr) * 2008-04-15 2010-09-24 Inst Rech Developpement Ird Sels de quinoleines 2-substituees
CA2731209A1 (en) 2008-07-28 2010-02-04 Eisai R&D Management Co., Ltd. Spiroaminodihydrothiazine derivatives
WO2010021680A2 (en) 2008-08-19 2010-02-25 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
CN102209721A (zh) 2008-09-11 2011-10-05 安姆根有限公司 作为β-分泌酶调节剂的螺四环化合物及其使用方法
TW201105650A (en) 2009-07-02 2011-02-16 Astrazeneca Ab New compounds
CN102812005B (zh) 2010-02-24 2014-12-10 生命医药公司 β-分泌酶抑制剂
US20120065195A1 (en) 2010-03-31 2012-03-15 Clark Christopher T Compounds for treating neurodegenerative diseases
WO2011130741A1 (en) 2010-04-16 2011-10-20 Array Biopharma Inc. Compounds for treating neurodegenerative diseases
WO2012019056A1 (en) 2010-08-05 2012-02-09 Amgen Inc. Amino-iso-indole, amino-aza-iso-indole, amino-dihydroisoquinoline and amino-benzoxazine compounds as beta-secretase modulators and methods of use
TW201219400A (en) 2010-09-24 2012-05-16 Array Biopharma Inc Compounds for treating neurodegenerative diseases
AR083953A1 (es) 2010-11-22 2013-04-10 Array Biopharma Inc Compuestos para tratar enfermedades neurodegenerativas
ES2566373T3 (es) 2011-10-10 2016-04-12 Astrazeneca Ab Inhibidores monofluoro beta-secretasa
US9000183B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000184B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000182B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab 2H-imidazol-4-amine compounds and their use as BACE inhibitors
US9000185B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cycloalkyl ether compounds and their use as BACE inhibitors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009539983A (ja) * 2006-06-12 2009-11-19 シェーリング コーポレイション 複素環式アスパルチルプロテアーゼ阻害薬
WO2010105179A2 (en) * 2009-03-13 2010-09-16 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
WO2011002408A1 (en) * 2009-07-02 2011-01-06 Astrazeneca Ab Novel compounds for treatment of neurodegeneration associated with diseases, such as alzheimer's disease or dementia
JP2014504300A (ja) * 2010-12-22 2014-02-20 アストラゼネカ・アクチエボラーグ 化合物及びbace阻害剤としてのその使用
JP2017008072A (ja) * 2010-12-22 2017-01-12 アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag 化合物及びbace阻害剤としてのその使用
JP6180325B2 (ja) * 2010-12-22 2017-08-16 アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag 化合物及びbace阻害剤としてのその使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BERGE S M: "PHARMACEUTICAL SALTS", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. V66 N1, JPN5012008762, 1 January 1977 (1977-01-01), US, pages 1 - 19, ISSN: 0003509983 *
GOULD P L: "SALT SELECTION FOR BASIC DRUGS", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. V33 N1/03, JPN5012008761, 1 January 1986 (1986-01-01), NL, pages 201 - 217, ISSN: 0003509984 *

Also Published As

Publication number Publication date
ES2618939T3 (es) 2017-06-22
CN104411697A (zh) 2015-03-11
SMT201700142T1 (it) 2017-05-08
US20140031379A1 (en) 2014-01-30
MA39259B1 (fr) 2018-09-28
ZA201500408B (en) 2016-10-26
MX2014014709A (es) 2015-03-04
AR105176A2 (es) 2017-09-13
RS55815B1 (sr) 2017-08-31
EP2864316B1 (en) 2016-12-14
NZ702742A (en) 2016-12-23
WO2013190302A1 (en) 2013-12-27
EP3064494A1 (en) 2016-09-07
HUE033376T2 (en) 2017-11-28
NI201400146A (es) 2016-09-21
PT2864316T (pt) 2017-02-24
MA37666B1 (fr) 2016-12-30
ME02633B (me) 2017-06-20
CL2014003374A1 (es) 2015-02-27
PH12014502803B1 (en) 2015-02-23
MA39259A1 (fr) 2017-12-29
DOP2014000268A (es) 2015-04-15
BR112014031531B1 (pt) 2022-08-02
AP2017009693A0 (en) 2017-01-31
CO7151486A2 (es) 2014-12-29
UA114196C2 (uk) 2017-05-10
RU2014148305A (ru) 2016-08-10
PL2864316T3 (pl) 2017-09-29
JP2018104448A (ja) 2018-07-05
PH12016500498A1 (en) 2017-04-10
AU2017254965A1 (en) 2017-11-23
HRP20170359T1 (hr) 2017-05-05
PE20150670A1 (es) 2015-06-03
CR20160202A (es) 2016-07-26
BR122016014302B1 (pt) 2022-08-23
MX354214B (es) 2018-02-19
EP2864316A1 (en) 2015-04-29
CY1119505T1 (el) 2018-03-07
MA37666A1 (fr) 2016-04-29
RU2638175C2 (ru) 2017-12-12
TWI639591B (zh) 2018-11-01
AP2014008137A0 (en) 2014-12-31
CN104411697B (zh) 2016-08-10
DK2864316T3 (en) 2017-03-20
CR20140571A (es) 2015-02-04
TWI588140B (zh) 2017-06-21
KR102123708B1 (ko) 2020-06-16
ECSP14032215A (es) 2015-12-31
AU2017254965B2 (en) 2019-05-09
CA2875589C (en) 2020-08-25
JP6509393B2 (ja) 2019-05-08
SG11201407934UA (en) 2015-01-29
AU2013279109B2 (en) 2017-08-31
BR122016014302A2 (pt) 2019-08-27
US10548882B2 (en) 2020-02-04
TW201730177A (zh) 2017-09-01
PH12014502803A1 (en) 2015-02-23
AU2013279109A1 (en) 2015-01-15
CA2875589A1 (en) 2013-12-27
HK1206349A1 (en) 2016-01-08
IL236131A0 (en) 2015-02-01
KR20150023388A (ko) 2015-03-05
AR091495A1 (es) 2015-02-11
TW201406745A (zh) 2014-02-16
BR112014031531A2 (pt) 2017-06-27
TN2014000491A1 (en) 2016-03-30
CN106279102A (zh) 2017-01-04
IN2014DN10088A (enrdf_load_stackoverflow) 2015-08-21
SI2864316T1 (sl) 2017-04-26
LT2864316T (lt) 2017-03-27
NZ727045A (en) 2018-06-29

Similar Documents

Publication Publication Date Title
JP6509393B2 (ja) カンシル酸塩
US20070197509A1 (en) Compositions and methods for modulating gated ion channels
JP6243921B2 (ja) Bace阻害剤
JP2015520220A (ja) シクロアルキルエーテル化合物およびbace阻害物質としてのその使用
JP2015520217A (ja) 2h−イミダゾール−4−アミン化合物およびbace阻害物質としてのその使用
JP2015520218A (ja) シクロヘキサン−1,2’−インデン−1’,2’’−イミダゾール化合物およびbace阻害物質としてのその使用
JP6185192B2 (ja) アミノチアジン化合物
HK1229787A1 (en) A process for the preparation of a camsylate salt ((1s)-(+)-10 camphorsulfonic acid) of (1r,1'r,4r)- 4-methoxy-5"-methyl-6'-[5-(prop-1-yn-1-yl)pyridin- 3-yl]-3'h-dispiro[cyclohexane-1,2'-inden-1'2'-imidazole]-4"-amine
HK1206349B (en) Camsylate salt of (1r,1'r,4r)- 4-methoxy-5"-methyl-6'-[5-(prop-1-yn-1-yl)pyridin- 3-yl]-3'h-dispiro[cyclohexane-1,2'-inden-1'2'-imidazole]-4"-amine and crystalline forms thereof for the treatment of a[beta]-related pathologies such as e.g. alzheimer's disease
JP5909554B2 (ja) V1aアンタゴニストとしてのオキシ−シクロヘキシル−4H,6H−5−オキサ−2,3,10b−トリアザ−ベンゾ[e]アズレン類
JP2006528206A (ja) オキシカム化合物の使用
JP2019524825A (ja) 選択的bace1阻害剤として有用な1,4−オキサジン

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160620

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160620

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170607

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171010